FDA Logo links to FDA home page
U.S. Food and Drug Administration
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | Dockets Home Page | Dockets Contacts and Location | Operating Status

horizonal rule

Dockets Management
Dockets Entered On January 13, 2005
Table of Contents
Docket # Title
1998P-0151 Introduction Of Downed Cattle Into The Food Supply
2000N-0504 Egg Safety Action Plan
2000N-1571 Enrofloxacin for Poultry: Opportunity for Hearing
2002N-0291 Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity
2003P-0270 Prohibit False and Misleading Labeling
2004D-0369 Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
2004N-0332 Agency Information Collection Activities: Proposed Collection; Comment Request; Medical Devices; Third Party Review under FDAMA
2004P-0003 Petition to reconsider the Food and Drug Administration's decision on the Med Watch complaint
2004P-0085 Esmolol Hydrochloride for injection ,2,500 mg/vital in a lyophilized form is suitable for evaluation under an ANDA
2004P-0149 ANDA Suitability for 2.5 mg oxycodone hydrochloride/325 mg acetaminophen and 5 mg oxycodone hydrochloride/325 mg acetaminophen
2005A-0014 Regarding hip joint metal constrained
2005A-0015 Request for Advisory Opinion Concerning "Orange Book" Listing of Patents
2005P-0013 Cefixime for Oral Suspension, 200 mg/mL, as an Abbreviated New Drug Applicaton(ANDA)
1998P-0151 Introduction Of Downed Cattle Into The Food Supply
C 7467 N. Semeniuk Vol #: 319
C 7468 S and H Wyck Vol #: 319
2000N-0504 Egg Safety Action Plan
C 364 J. Trenchik Vol #: 27
C 365 K. Eichelberger Vol #: 27
C 366 K. Sprague Vol #: 27
C 367 R. Houck, Esq Vol #: 27
C 368 G. Philbin Vol #: 27
C 369 C. Wooldridge Vol #: 27
2000N-1571 Enrofloxacin for Poultry: Opportunity for Hearing
EXB 923 Bayer Corporation Vol #: 474
EXB 924 Bayer Corporation Vol #: 474
EXB 925 Bayer Corporation Vol #: 474
EXB 926 Bayer Corporation Vol #: 474
EXB 927 Bayer Corporation Vol #: 474
EXB 928 Bayer Corporation Vol #: 474
EXB 929 Bayer Corporation Vol #: 474
EXB 930 Bayer Corporation Vol #: 474
EXB 931 Bayer Corporation Vol #: 474
EXB 932 Bayer Corporation Vol #: 474
EXB 933 Bayer Corporation Vol #: 474
EXB 934 Bayer Corporation Vol #: 474
EXB 935 Bayer Corporation Vol #: 474
EXB 936 Bayer Corporation Vol #: 474
EXB 937 Bayer Corporation Vol #: 474
EXB 938 Bayer Corporation Vol #: 474
EXB 939 Bayer Corporation Vol #: 474
EXB 940 Bayer Corporation Vol #: 474
EXB 941 Bayer Corporation Vol #: 474
EXB 942 Bayer Corporation Vol #: 474
EXB 943 Bayer Corporation Vol #: 474
EXB 944 Bayer Corporation Vol #: 474
EXB 945 Bayer Corporation Vol #: 474
EXB 946 Bayer Corporation Vol #: 474
EXB 947 Bayer Corporation Vol #: 474
EXB 948 Bayer Corporation Vol #: 474
EXB 949 Bayer Corporation Vol #: 474
EXB 950 Bayer Corporation Vol #: 474
EXB 951 Bayer Corporation Vol #: 474
EXB 952 Bayer Corporation Vol #: 474
EXB 953 Bayer Corporation Vol #: 474
2002N-0291 Proposal to Debar Baldev Raj Bhutani;Notice of Opportunity
LET 2 Raj Bhutani, Ph.D. Vol #: 4
2003P-0270 Prohibit False and Misleading Labeling
C 84 L. Cardinale Vol #: 9
2004D-0369 Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by Bioengineered Plants Intended for Food Use
EMC 563 R Stang Vol #: 8
EMC 564 R Nussler Vol #: 8
EMC 565 T Balch Vol #: 8
EMC 566 J Ward Vol #: 8
EMC 567 J Yanulavich Vol #: 8
EMC 568 C Flintermann Vol #: 8
EMC 569 D Augustine Vol #: 8
EMC 570 T Amesse Vol #: 8
EMC 571 L Hultgren Vol #: 8
EMC 572 M Vaughn Vol #: 8
EMC 573 E Catherine Vol #: 8
EMC 574 T Simpson Vol #: 8
EMC 575 T Murphy Vol #: 8
EMC 576 M Cenci Vol #: 8
EMC 577 D Cesari Vol #: 8
EMC 578 J Scott Vol #: 8
EMC 579 E Hunt Vol #: 8
EMC 580 H Robinson Vol #: 8
EMC 581 C Snyder Vol #: 8
EMC 582 I Pongratz Vol #: 8
EMC 583 G Schneider Vol #: 8
EMC 584 T Wood Vol #: 8
EMC 585 E Mathis Vol #: 8
EMC 586 P Haynes Vol #: 8
EMC 587 H Selin Vol #: 8
EMC 588 I Hagemann Vol #: 8
EMC 589 G Lizotte Vol #: 8
EMC 590 J Pizzino MD MPH Vol #: 8
EMC 591 L McElroy Vol #: 8
EMC 592 C Hamil Vol #: 8
EMC 593 T Eisenberg Vol #: 8
EMC 594 K Klapprott Vol #: 8
EMC 595 E von Dreele Vol #: 8
EMC 596 E Chorush Vol #: 8
EMC 597 S Goodson Vol #: 8
EMC 598 M Smith Vol #: 8
EMC 599 L Wood Vol #: 8
EMC 600 B Reynolds Vol #: 8
EMC 601 RM Fisher Vol #: 8
EMC 602 Number not used Vol #: 8
EMC 603 C Bales Vol #: 8
EMC 604 S Brown Vol #: 8
EMC 605 B Sashaw Vol #: 8
EMC 606 D Davis Vol #: 8
EMC 607 D Rusch Vol #: 8
EMC 608 W Smith Vol #: 8
EMC 609 T Heinzen Vol #: 8
EMC 610 L Phillips Vol #: 8
EMC 611 E Treimel Vol #: 8
EMC 612 M White Vol #: 8
EMC 613 M Gradziel Vol #: 8
EMC 614 N WHite Vol #: 8
EMC 615 H Irby Vol #: 8
EMC 616 D Langstaff Vol #: 8
EMC 617 B Rose Vol #: 8
EMC 618 S Berlin Vol #: 8
EMC 619 T Hougham Vol #: 8
EMC 620 E Eschweiler Vol #: 8
EMC 621 B Humphrey Vol #: 8
EMC 622 E Burke Vol #: 8
EMC 623 M Ritter-Brown Vol #: 8
EMC 624 S Stone Vol #: 8
EMC 625 L Corxson Vol #: 8
EMC 626 J Meunier Vol #: 8
EMC 627 S Nickerson Vol #: 8
EMC 628 L Wood Vol #: 8
EMC 629 D Gundlach Vol #: 8
EMC 630 J Johnson Vol #: 8
EMC 631 N Muster Vol #: 8
EMC 632 B Tomasini Vol #: 8
EMC 633 H Richmond Vol #: 8
EMC 634 A Osowski Vol #: 8
EMC 635 N Fulmer Vol #: 8
EMC 636 J Burns Vol #: 8
EMC 637 M Rogers Vol #: 8
EMC 638 K Brown Vol #: 8
EMC 639 J Franks Vol #: 8
EMC 640 M Coats Vol #: 8
EMC 641 A Winters Vol #: 8
EMC 642 J Kennedy-Alexander Vol #: 8
EMC 643 R Janusko Vol #: 8
EMC 644 T Piegdon Vol #: 8
EMC 645 C Schnackel Vol #: 8
EMC 646 E Duell Vol #: 8
EMC 647 L Allen Vol #: 8
EMC 648 V Giella Vol #: 8
EMC 649 C Browning Vol #: 8
EMC 650 R Craig Vol #: 8
EMC 651 R Spring Vol #: 8
EMC 652 K Dalenberg Vol #: 8
EMC 653 J R Stevens Vol #: 8
EMC 654 H Spalding Vol #: 8
EMC 655 M Maisenhalter Vol #: 8
EMC 656 R Wright Vol #: 8
EMC 657 T S McMillin Vol #: 8
EMC 658 J Passante Vol #: 8
EMC 659 D Parker Vol #: 8
EMC 660 J Mikus Vol #: 8
2004N-0332 Agency Information Collection Activities: Proposed Collection; Comment Request; Medical Devices; Third Party Review under FDAMA
NAL 1 FDA Vol #: 1
SS 1 SUPPORTING STATEMENT Vol #: 1
2004P-0003 Petition to reconsider the Food and Drug Administration's decision on the Med Watch complaint
ACK 4 HFA-305 to Bill G. Pierson #907177 Vol #: 1
PSA 3 Bill G. Pierson Vol #: 1
2004P-0085 Esmolol Hydrochloride for injection ,2,500 mg/vital in a lyophilized form is suitable for evaluation under an ANDA
RC 1 Bedford Laboratories Vol #: 1
2004P-0149 ANDA Suitability for 2.5 mg oxycodone hydrochloride/325 mg acetaminophen and 5 mg oxycodone hydrochloride/325 mg acetaminophen
LET 1 HFD-600 to Endo Pharmaceuticals, Inc. Vol #: 1
2005A-0014 Regarding hip joint metal constrained
ACK 1 HFA-305 to Bill G. Pierson #907177 Vol #: 1
AP 1 Bill G. Pierson #907177 Vol #: 1
2005A-0015 Request for Advisory Opinion Concerning "Orange Book" Listing of Patents
ACK 1 GlaxoSmithKline Vol #: 1
AP 1 GlaxoSmithKline Vol #: 1
2005P-0013 Cefixime for Oral Suspension, 200 mg/mL, as an Abbreviated New Drug Applicaton(ANDA)
ACK 1 Lupin Pharmaceuticals, Inc. Vol #: 1
CP 1 Lupin Pharmaceuticals, Inc. Vol #: 1

Page created on December 14, 2005 kk

horizonal rule

Dockets Home| Dockets Contacts and Location | Operating Status | Item Code Definitions | Federal Register
FDA Home Page | Search FDA Site | A-Z Index | Contact FDA | Privacy | Accessibility

FDA/Dockets Management